NCT07037953Completed
Serum circ_DLGAP4, lncRNA KCNQ1OT1, and Their Targets by Erythropoietin Resistance in Chronic Kidney Disease
Association of Serum circ_DLGAP4, lncRNA KCNQ1OT1, and Their Targets miR-9 and SOX7 With Early Diagnosis, Erythropoietin Resistance and Worse Clinical Outcomes of Chronic Kidney Disease: Insights From Hemodialysis Patients
Source: ClinicalTrials.gov · Last updated 7 Apr 2026
Brief summary (registry, in English)
Non-coding RNAs have evolved as biomarkers and as phased and specific therapeutic targets for chronic kidney disease (CKD). However, their clinical significance in CKD patients is largely unexplored. Anemia resistant to erythropoietin-stimulating agents (ESAs) is a risk factor for all-cause mortality of CKD patients. This study investigated the potential association of serum circ\_DLGAP4, lncRNA KCNQ1OT1, miR-9, and their target SOX7 with the early diagnosis, prognosis, and worse clinical outcomes in CKD patients with different stages, including those on maintenance hemodialysis (MHD). The clinical correlations of these markers in CKD patients were explored; particularly their possible association with ESA resistance in MHD patients. An analytical observational case-controlled cross-sectional study was conducted on CKD patients. Participants were enrolled to control group \[60 healthy controls\], on-hemodialysis (non-HD) group \[60 CKD Grade 2-4 patients with no hemodialysis\], and hemodialysis (HD) Group \[60 CKD Grade 5 patients undergoing MHD\]. Demographic, clinical, laboratory data, and drug history were recorded. ESA hypo-responsiveness index (EHRI) was calculated. Molecular pathway analysis was conducted using bioinformatics. RT-qPCR and ELISA techniques were used in gene expression and SOX7 protein assays, respectively.
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 180 (actual)
- First submitted
- 10 Jun 2025
- Start date
- Aug 2024
- Primary completion date
- Jan 2025
- Lead sponsor
- Ain Shams University
- Diseases
- Chronic kidney disease
- NCT number
- NCT07037953
What you commit to
- Study type: Observational
- Participants enrolled: 180
- From Aug 2024 to the primary completion date, Jan 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- kidney transplant recipients,
- individuals in critical conditions, those with acute kidney injury, ischemic heart disease, cancer, or those receiving chemotherapy, or having cognitive impairment
Age
- Subjects having \< 18 years of age,
Other
- non-compliant persons,
- smokers,
- patients with low risk of CKD (category G1),
Who the study is looking for
- adult patients (\> 18 years) with a final clinical diagnosis of CKD with a category G2-G5
- mild to severe albuminuria (A1-A3),
- patients with an eGFR \< 15 mL/min/1.73 m2 (kidney failure or ESKD) undergoing HD.
Age in the registry: 18 years to - · Sex: All · Accepts healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Unit of Renal Failure Therapy and Surgery, Kasr Al-Ainy Hospital, Faculty of Medicine, Cairo, Egypt, and the Hemodialysis Unit, New Cairo Specialized Hospital, Cairo, Egypt Coordinator of this site? Confirm its status | Cairo | Egypt | Unknown status |
Related publications
- Integrative analysis of circ_DLGAP4, lncRNA KCNQ1OT1, and the miR-9/SOX7 interaction network in chronic kidney disease progression: a case-control study.Funct Integr Genomics · 2026 · PMID 42400831
This page is information, not medical advice. Discuss any trial with your doctor.